Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial

Abroad (travel likely)RecruitingPHASE2

Conditions

Acute Lymphoblastic Leukaemia · Acute Leukemia of Ambiguous Lineage · Chronic Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic Syndrome · Acute Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University Hospitals Birmingham NHS Foundation Trust, Birmingham, England, United Kingdom
Contact: Study coordinator (Senior Haematology Research Sister) · HaematologyCancerResearch@uhb.nhs.uk · 01213714351
Contact: Principal Investigator (Francesca Kinsella)
Leeds Teaching Hospital NHS Trust, Leeds, England, United Kingdom
Contact: Study coordinator (Principal Investigator) · anjum.khan@nhs.net · 01132068561
University College London Hospitals NHS Trust, London, England, United Kingdom
Contact: Study coordinator (BMT Trials) · uclh.bmttrials@nhs.net
Contact: Principal Investigator (Panagiotis Kottaridis)
Kings College NHS Foundation Trust, London, England, United Kingdom
Contact: Study coordinator (Principal Investigator) · p.krishnamurthy@nhs.net
Contact: Principal Investigator (Pramila Krishnamurthy)
Imperial College Healthcare NHS Trust, London, England, United Kingdom
Contact: Study coordinator (Senior Research Operations Manager) · Eleni.Vourvou@nhs.net · 02037048452
Royal Mardsen Hostpital, London, United Kingdom
Contact: Study coordinator (Haemato-Oncology Department) · Emma.Nicholson@rmh.nhs.uk · 0208915 6187
Contact: Principal Investigator (Emma Nicholson)
Manchester University NHS Foundation Trust, Manchester, United Kingdom
Contact: Study coordinator (Farshi Pakhshan) · Pakhshan.Farshi@mft.nhs.uk · 01612761234
Manchester University NHS Trust, Manchester, United Kingdom
Contact: Study coordinator (Fiona Dignan) · Alice.Cui@mft.nhs.uk · 0161 276 4178

Study leads

Jiri Pavlu
Principal Investigator
Imperial College London

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Acute Myeloid Leukemia · Accelerated Phase Chronic Myeloid Leukemia · Blast Phase Chronic Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Ghent, Belgium · Paris, France

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Seattle, United States

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Acute Lymphoblastic Leukemia in Remission · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Acute Myeloid Leukemia in Remission

Abroad (travel likely)RecruitingPHASE1, PHASE2

Seattle, United States

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Acute Myeloid Leukemia in Remission · Myelodysplastic Syndromes · Chronic Myeloid Leukemia in Remission

Abroad (travel likely)RecruitingPHASE2

Antwerp, Belgium · Bruges, Belgium